The Food and Drug Administration (FDA) stated COVID-19 monoclonal antibody treatment bebtelovimab from Eli Lilly is no longer authorized for emergency use in the U.S. The treatment is not expected to be effective at neutralizing the two most dominant omicron subvariants in the country right now, omicron subvariants BQ.1 and BQ.1.1.

The announcement was made November 30, 2022.

Eli Lilly and its distributors have paused distribution of bebtelovimab until further notice and the Administration for Strategic Preparedness and Response has also paused the fulfillment of any pending requests for the drug.

Read the full article here.